Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788639 · ClinicalTrials.gov registry record
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
A clinical trial of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06788639 is a study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 300 participants, above the 181-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06788639, a study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
Conditions Studied
Interventions
- BIOLOGICAL Lisocabtagene maraleucel
Study Locations (1)
Wisconsin
- Center for International Blood and Marrow Transplant Research (CIBMTR) - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2044-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06788639
The ClinicalTrials.gov registry entry for NCT06788639 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (66% higher). The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which Lisocabtagene maraleucel is the first listed.
NCT06788639 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06788639 about?
NCT06788639 is a clinical study titled "A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting". The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
What is the current status of trial NCT06788639?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-02-04. Estimated completion is 2044-06-30.
What conditions does trial NCT06788639 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT06788639?
The interventions under investigation include: Lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06788639?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788639 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RECRUITING
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Small Lymphocytic Lymphoma (SLL)
All registered trials for this condition
Wisconsin
All trials with a study site in Wisconsin
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.